Global Focal Segmental Glomerulosclerosis Drugs Market, By Drugs (Corticosteroids, Immunosuppressive Drugs, ACE inhibitors, A.R. Blockers, Diuretics, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Focal Segmental Glomerulosclerosis Drugs Market Analysis and Size
The occurrence of focal segmental glomerulosclerosis is comparatively high as compared to other glomerular diseases. Currently, there are no FDA-approved therapies for focal segmental glomerulosclerosis. The therapeutic market size of focal segmental glomerulosclerosis drugs in the U.S. mostly accounts for off-label treatment options, such as non-immune therapy and immunotherapy. COVID-19 also had a major impact on market growth.
Data Bridge Market Research analyses a growth rate in the global focal segmental glomerulosclerosis drugs market in the forecast period 2023-2030. The expected CAGR global focal segmental glomerulosclerosis drugs market tends to be around 8.20% in the mentioned forecast period. The market was valued at USD 12.6 billion in 2022 and would grow to USD 23.7 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Focal Segmental Glomerulosclerosis Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Corticosteroids, Immunosuppressive Drugs, ACE inhibitors, A.R. Blockers, Diuretics, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare (U.K.), Wockhardt (India), Alkem Labs (India), Otsuka Pharmaceutical Co., Ltd (Japan)
|
|
Market Opportunities
|
|
Market Definition
Focal segmental glomerulosclerosis is a kind of renal disorder affecting the small filtering unit of kidneys called glomeruli that involves kidney scarring. It is caused by multiple factors, such as autoimmune disorders, genetic factors, infection in other body parts, and sclerotic diseases. It is a rare disease affecting kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, obstructive sleep apnea, birth, sickle cell anemia, and viruses such as HIV.
Global Focal Segmental Glomerulosclerosis Drugs Market Dynamics
Drivers
- Increased Prevalence of Focal segmental glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS), a rare health condition, affects around 210,200 patients worldwide, and about 14,000 to 16,000 new cases are diagnosed annually. The increasing numbers and the considerable opportunities are boosting the market's growth.
- Growing Elderly Population
Life expectancy is increasing all over the globe, which has led to an increase in the elderly population. This trend positively impacts the industry by increasing the occurrence of the disease and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) has been witnessed, resulting in the sound growth of the global focal segmental glomerulosclerosis drugs market during the forecast period. Thus, it creates more opportunities for market growth.
Opportunities
- Higher Therapeutic Options
The latest therapy for primary focal segmental glomerular sclerosis includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Moreover, steroid therapy is among the most basic and standard treatments with oral prednisone. Some of the main developing companies that have their potential drug candidates in the pipeline are Chemocentryx, Pharmaceuticals, Retrophin Inc., Reata, and Vertex Pharmaceuticals. This boosts market growth.
- Increased Clinical Research Activities
Increasing R&D for focal segmental glomerulosclerosis drugs by several key manufacturers is also fuelling the growth of the focal segmental glomerulosclerosis drugs market. For instance, Pfizer Inc. is going through a clinical trial to evaluate its drug, PF-06730512, in adults with primary focal segmental glomerulosclerosis. This drug is currently in Phase II study and is expected to complete in June 2021. Thus, all these research activities create many market growth opportunities.
Restraints/Challenges
- Lack of Medical Care
The lack of medical care in undeveloped economies may restrain the growth of the focal segmental glomerulosclerosis drugs market during the forecast period. Not much awareness can lead to the unavailability of treatment and limit market growth.
- High Cost
The huge expenditure associated with drug therapy, dialysis, and kidney transplant hamper the market growth. The huge drug development and the related processes are hindering the growth of the market.
This global focal segmental glomerulosclerosis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global focal segmental glomerulosclerosis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
COVID-19 Impact on Global Focal Segmental Glomerulosclerosis Drugs Market
The global focal segmental glomerulosclerosis drugs market growth has been significantly impacted because of COVID-19 worldwide. The huge severity of the COVID-19 pandemic and its following outbreaks have led policymakers, regulators, market players, and even the general population to come forward and fight against the crisis. The collaborations and engagements across the value chain have thus paved the way to numerous latest healthcare models, business and operating models for the economy, and new ways of working.
Global Focal Segmental Glomerulosclerosis Drugs Market Scope
The global focal segmental glomerulosclerosis drugs market is segmented on the basis of treatment, route of administration, distribution channel, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Corticosteroids
- Immunosuppressive Drugs
- ACE inhibitors
- A.R. Blockers
- Diuretics
- Others
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Focal Segmental Glomerulosclerosis Drugs Market Regional Analysis/Insights
The global focal segmental glomerulosclerosis drugs market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global focal segmental glomerulosclerosis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for the global focal segmental glomerulosclerosis drugs market throughout the forecasted period due to growing initiatives taken by the government and pharmaceutical organizations to spread awareness and the presence of generic manufacturers.
North America dominates the market due to the advancement of technology for focal segmental glomerulosclerosis drugs and increasing initiatives several pharmaceutical organizations take to generate novel formulations.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Focal Segmental Glomerulosclerosis Drugs Market Share Analysis
The global focal segmental glomerulosclerosis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global focal segmental glomerulosclerosis drugs market.
Key players operating in the global focal segmental glomerulosclerosis drugs market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.S.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Accord Healthcare (U.K.)
- Wockhardt (India)
- Alkem Labs (India)
- Otsuka Pharmaceutical Co., Ltd (Japan)
Research Methodology: Focal Segmental Glomerulosclerosis Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-